Promore Pharma AB (publ), under name change to PMD Device Solutions AB (the “Company”), has received approval for continued trading on Nasdaq First North Growth Market and publishes a company description prepared in connection with the name and business change of the Company as a result of the planned acquisition of PMD Device Solutions AB.
On 29 November 2023, the Company announced the reverse acquisition of PMD Device Solutions AB, subject to resolution by the extraordinary general meeting of the Company on 29 December 2023 (the “Reverse Acquisition”). The Company has today received approval from Nasdaq Stockholm for continued trading on Nasdaq First North Growth Market, subject to customary conditions. The Company also publishes a company description due to the Reverse Acquisition and the continued listing. The company description is available at http://www.promorepharma.com.
Information about PMD
PMD develops and sells medical products for respiratory monitoring. Its primary product is RespiraSense™, a solution used for monitoring respiratory rate to detect deterioration of a patient’s general condition early and to avoid preventable respiratory failure and adverse patient outcomes. RespiraSense™ is, to the PMD’s knowledge, the world’s only continuous, motion-tolerant respiratory rate monitor delivering class-leading reliability in measuring respiratory rate. PMD received FDA approval for RespiraSense™ in 2022. RespiraSense™ is a novel technology and today used in 25 hospitals across United Kingdom and Ireland. PMD seeks to continue increasing its market share in the United Kingdom, with Germany and the United States to follow with initial market access activities.